Trial Profile
A Phase 1b, Multicenter, Open-label, Staggered-dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of CC-90001 for 3 Months in Patients With Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BMS 986360 (Primary)
- Indications Pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 24 May 2017 Safety profile results of CC-90001 using patient data from Phase 1b and one other phase 1 target engagement study, presented at the 113th International Conference of the American Thoracic Society
- 30 Mar 2017 Status changed from recruiting to completed.
- 29 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.